OncoMatch/Clinical Trials/NCT04596670
68Ga-ICAM-1pep PET/CT in Cancer Patients
Is NCT04596670 recruiting? Yes, currently enrolling (Jun 2026). This Early Phase 1 trial studies 68Ga-ICAM-1pep for cancer.
Treatment: 68Ga-ICAM-1pep — This is an open-label positron emission tomography/computed tomography (PET/CT) study to investigate the clinical predictive value of 68Ga-ICAM-1pep in metastatic cancer patients receiving radiotherapy. A single dose of 2.96 MBq/kg body weight of 68Ga-ICAM-1pep will be injected intravenously. The visual and semiquantitative methods will be used to assess the PET/CT images.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Lab requirements
Blood counts
Low WBC (less than 3 x 10^9/L) excluded
Kidney function
severe renal dysfunction excluded
Liver function
severe hepatic dysfunction excluded
Severe hepatic or renal dysfunction; Low WBC (less than 3 x 10^9/L)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT04596670 currently recruiting?
Yes, this trial is currently recruiting patients.
Is there an age limit?
Yes. Patients must be 80 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify